Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment

Figure 1

A. Radiographs of treated and untreated LuCaP 23.1 bone tumors. Extensive new bone formation stimulated by LuCaP 23.1 is visible in the control tibiae. Although substantial bone formation is also visible with ZOL and ZOL + docetaxel, these tibiae exhibit decreased periosteal activity compared to the control and docetaxel-treated tibiae. B.-E. Histological appearance of treated and untreated LuCaP 23.1 bone tumors. Sections stained with Goldner reagent show marrow or tumored areas in pink and bone in green. The growth plate is marked with the letter G. The ZOL- (C) and ZOL + docetaxel-treated groups (E) exhibit substantial increases in bone volume and decreases in tumor volume compared to the control (B) and docetaxel-treated (D) groups. F. Bone mineral density (BMD) measurements at sacrifice. BMD was measured for the non-tumored and tumored legs of all four treatment groups. BMD was higher in tumored tibiae than in non-tumored tibiae, but there were no significant differences among the four treatment groups.

Back to article page